Shares of Intrexon Corp. (NYSE:XON) traded down 1.8% on Monday . The company traded as low as $26.15 and last traded at $26.23, with a volume of 1,213,444 shares. The stock had previously closed at $26.72.

A number of analysts have recently weighed in on the stock. Wunderlich restated a “buy” rating and issued a $50.00 target price on shares of Intrexon Corp. in a report on Thursday, July 7th. Stifel Nicolaus restated a “buy” rating and issued a $57.00 target price on shares of Intrexon Corp. in a report on Wednesday, June 29th. Griffin Securities reiterated a “buy” rating and set a $65.00 price target on shares of Intrexon Corp. in a report on Tuesday, June 7th. Zacks Investment Research downgraded shares of Intrexon Corp. from a “strong-buy” rating to a “hold” rating in a report on Friday, May 6th. Finally, JMP Securities initiated coverage on shares of Intrexon Corp. in a report on Tuesday, May 3rd. They set an “outperform” rating and a $42.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $49.96.

The company’s market capitalization is $3.10 billion. The stock’s 50 day moving average is $26.72 and its 200-day moving average is $30.00.

Intrexon Corp. (NYSE:XON) last issued its quarterly earnings data on Tuesday, May 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.35. During the same period in the previous year, the company earned $0.25 EPS. The firm had revenue of $43.40 million for the quarter, compared to analyst estimates of $46.26 million. The company’s revenue was up 28.4% on a year-over-year basis. Equities analysts anticipate that Intrexon Corp. will post ($1.32) earnings per share for the current year.

In related news, CEO Randal J. Kirk acquired 41,830 shares of Intrexon Corp. stock in a transaction dated Friday, May 13th. The stock was acquired at an average price of $23.92 per share, for a total transaction of $1,000,573.60. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Several hedge funds recently modified their holdings of XON. Iridian Asset Management LLC CT increased its stake in shares of Intrexon Corp. by 82.3% in the fourth quarter. Iridian Asset Management LLC CT now owns 3,454,261 shares of the company’s stock valued at $104,146,000 after buying an additional 1,559,672 shares in the last quarter. Morgan Stanley increased its stake in shares of Intrexon Corp. by 12.6% in the fourth quarter. Morgan Stanley now owns 3,162,236 shares of the company’s stock valued at $95,342,000 after buying an additional 354,559 shares in the last quarter. Oracle Investment Management Inc. increased its stake in shares of Intrexon Corp. by 15.9% in the fourth quarter. Oracle Investment Management Inc. now owns 932,585 shares of the company’s stock valued at $28,117,000 after buying an additional 127,708 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Intrexon Corp. by 44.8% in the fourth quarter. Wells Fargo & Company MN now owns 274,040 shares of the company’s stock valued at $8,262,000 after buying an additional 84,759 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in shares of Intrexon Corp. by 30.1% in the fourth quarter. New York State Common Retirement Fund now owns 212,875 shares of the company’s stock valued at $6,418,000 after buying an additional 49,290 shares in the last quarter.

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.